This NDC is on FDA's drug shortage list (posted Mar 13, 2023)
Product Information
METHOTREXATE 250 MG/10 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $3.1283 per ML under NDC 63323012310. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Feb 26, 1999. Its Orange Book therapeutic-equivalence code is AP.
The High Outlier badge above means this manufacturer's average price in the METHOTREXATE SODIUM market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323012310
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRA-ARTERIAL; INTRAMUSCULAR; INTRAVENOUS
Effective Date
8/19/2026
Active Ingredients
METHOTREXATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA040263FDA Approved
2/26/1999
TE Code
AP
On Market Since
9/10/2001
Pharmacological Classes
Price Statistics
The NADAC for METHOTREXATE 250 MG/10 ML VIAL has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 26.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.1283 per ML |
|---|---|
| All-time high | $3.5278 (Jul 15, 2015) |
| All-time low | $2.4714 (Nov 28, 2013) |
| 52-week high | $3.3602 |
| 52-week low | $3.0533 |
| Median price | $3.2008 |
| Average price | $3.1760 |
| Largest weekly change | -20.7% (Jul 17, 2024) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the METHOTREXATE SODIUM market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of METHOTREXATE 250 MG/10 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 250 MG/10 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $3.1283 per ML (NDC 63323012310), effective Aug 19, 2026.
How has the price of METHOTREXATE 250 MG/10 ML VIAL changed over time?
Over the history we have for it, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has risen 26.6%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for METHOTREXATE 250 MG/10 ML VIAL?
Since Nov 28, 2013, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has ranged from a low of $2.4714 (Nov 28, 2013) to a high of $3.5278 (Jul 15, 2015), with a median of $3.2008 per ML.
Are there cheaper alternatives to METHOTREXATE 250 MG/10 ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of METHOTREXATE 250 MG/10 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures METHOTREXATE 250 MG/10 ML VIAL?
METHOTREXATE 250 MG/10 ML VIAL (NDC 63323012310) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.
Is METHOTREXATE 250 MG/10 ML VIAL in shortage?
Yes — NDC 63323012310 is currently listed in FDA's drug shortage database (posted Mar 13, 2023).